Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Presenilin family protein | 0.0239 | 0.1471 | 0.1471 |
Schistosoma mansoni | subfamily A22A unassigned peptidase (A22 family) | 0.0239 | 0.1471 | 0.1197 |
Trichomonas vaginalis | Clan AD, family A22, presenilin-like aspartic peptidase | 0.0239 | 0.1471 | 1 |
Loa Loa (eye worm) | gamma-secretase subunit pen-2 | 0.0224 | 0.1332 | 0.1332 |
Trichomonas vaginalis | Clan AD, family A22, presenilin-like aspartic peptidase | 0.0239 | 0.1471 | 1 |
Echinococcus multilocularis | gamma secretase subunit aph 1 | 0.1138 | 1 | 1 |
Schistosoma mansoni | gamma-secretase subunit aph-1 | 0.1138 | 1 | 1 |
Brugia malayi | hypothetical protein | 0.0116 | 0.031 | 0.031 |
Loa Loa (eye worm) | gamma-secretase subunit aph-1 | 0.1138 | 1 | 1 |
Echinococcus multilocularis | presenilin | 0.0239 | 0.1471 | 0.1197 |
Trypanosoma cruzi | Aph-1 protein, putative | 0.0443 | 0.3413 | 1 |
Brugia malayi | gamma-secretase subunit pen-2 | 0.0224 | 0.1332 | 0.1332 |
Trichomonas vaginalis | Clan AD, family A22, presenilin-like aspartic peptidase | 0.0239 | 0.1471 | 1 |
Trypanosoma brucei | Aph-1 protein, putative | 0.0443 | 0.3413 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0116 | 0.031 | 0.031 |
Entamoeba histolytica | presenilin 1 peptidase, putative | 0.0239 | 0.1471 | 0.5 |
Echinococcus granulosus | gamma secretase subunit aph 1 | 0.1138 | 1 | 1 |
Leishmania major | presenilin-like aspartic peptidase, putative,presenilin-like aspartic peptidase, clan AD, family A22A, putative | 0.0239 | 0.1471 | 0.5 |
Echinococcus granulosus | presenilin | 0.0239 | 0.1471 | 0.1197 |
Echinococcus multilocularis | presenilin enhancer 2 | 0.0224 | 0.1332 | 0.1054 |
Toxoplasma gondii | hypothetical protein | 0.0084 | 0 | 0.5 |
Echinococcus granulosus | presenilin enhancer 2 | 0.0224 | 0.1332 | 0.1054 |
Brugia malayi | hypothetical protein | 0.0116 | 0.031 | 0.031 |
Trypanosoma cruzi | Aph-1 protein, putative | 0.0443 | 0.3413 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.